Listed

HeartSciences Inc.

HSCSNasdaqCIK 1468492FinancialsFiscal year ends Apr 30

Latest reported revenue, Q1 FY2027$2.1kRevenue, Q1 FY2027, three months to 2026-07-31$2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figureThree months to Jul 31, 2026, from the 10-Q filed Sep 14, 2026.

Latest quarter: Q1 FY2027

Three months to Jul 31, 2026, against the same quarter a year earlier.

  • Revenue$2.1kRevenue, Q1 FY2027, three months to 2026-07-31$2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure+10.5% on a year earlier
  • Gross margin63.8%Gross margin, Q1 FY2027, three months to 2026-07-31. gross profit / revenueGross profit: $1.3k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure+3.8 pts on a year earlier
  • Operating margin−139956.7%Operating margin, Q1 FY2027, three months to 2026-07-31. operating income / revenueOperating income: −$2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure−41318.8 pts on a year earlier
  • Net margin−151064.0%Net margin, Q1 FY2027, three months to 2026-07-31. net income / revenueNet income: −$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure−42906.4 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$2.1kGross margin 63.8%
Diluted EPS−$0.85, Q2 FY2026
Free cash flow−$1.7m, Q4 FY2026
HeartSciences Inc., key figures for the last eight quarters
Line itemUnitQ2 FY20252024-10-31Q3 FY20252025-01-31Q4 FY20252025-04-30Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31Q4 FY20262026-04-30Q1 FY20272026-07-31Shape over the periods
Revenue$knot reported (Revenue not reported)0.0Revenue, Q3 FY2025, three months to 2025-01-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-16, accession 0001437749-26-008399.Report this figure4.4Revenue, Q4 FY2025, three months to 2025-04-30$4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figure1.9Revenue, Q1 FY2026, three months to 2025-07-31$1.9k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure2.4Revenue, Q2 FY2026, three months to 2025-10-31$2.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figure0.0Revenue, Q3 FY2026, three months to 2026-01-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-16, accession 0001437749-26-008399.Report this figure0.0Revenue, Q4 FY2026, three months to 2026-04-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figure2.1Revenue, Q1 FY2027, three months to 2026-07-31$2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Revenue of zero not reported)56.8%Gross margin, Q4 FY2025, three months to 2025-04-30. gross profit / revenueGross profit: $2.5k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figure60.0%Gross margin, Q1 FY2026, three months to 2025-07-31. gross profit / revenueGross profit: $1.1k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $1.9k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure58.3%Gross margin, Q2 FY2026, three months to 2025-10-31. gross profit / revenueGross profit: $1.4k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Revenue: $2.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)63.8%Gross margin, Q1 FY2027, three months to 2026-07-31. gross profit / revenueGross profit: $1.3k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure
Operating margin%not reported (Revenue not reported)not reported (Revenue of zero not reported)(44147.1%)Operating margin, Q4 FY2025, three months to 2025-04-30. operating income / revenueOperating income: −$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figure(98637.8%)Operating margin, Q1 FY2026, three months to 2025-07-31. operating income / revenueOperating income: −$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $1.9k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure(85713.2%)Operating margin, Q2 FY2026, three months to 2025-10-31. operating income / revenueOperating income: −$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Revenue: $2.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(139956.7%)Operating margin, Q1 FY2027, three months to 2026-07-31. operating income / revenueOperating income: −$2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue of zero not reported)(48145.5%)Net margin, Q4 FY2025, three months to 2025-04-30. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figure(108157.6%)Net margin, Q1 FY2026, three months to 2025-07-31. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $1.9k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure(97179.4%)Net margin, Q2 FY2026, three months to 2025-10-31. net income / revenueNet income: −$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Revenue: $2.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(151064.0%)Net margin, Q1 FY2027, three months to 2026-07-31. net income / revenueNet income: −$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Revenue: $2.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-14, accession 0001437749-26-030319.Report this figure
Diluted EPS$ per share(2.27)Diluted EPS, Q2 FY2025, three months to 2024-10-31−$2.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figure(2.57)Diluted EPS, Q3 FY2025, three months to 2025-01-31−$2.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-03-13, accession 0000950170-25-038699.Report this figurenot reported (Diluted EPS not reported)(1.58)Diluted EPS, Q1 FY2026, three months to 2025-07-31−$1.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-09-11, accession 0001468492-25-000010.Report this figure(0.85)Diluted EPS, Q2 FY2026, three months to 2025-10-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-15, accession 0001193125-25-319203.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$knot reported (Capital expenditure not reported)(1,620)Free cash flow, Q3 FY2025, three months to 2025-01-31. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-16, accession 0001437749-26-008399. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-03-16, accession 0001437749-26-008399. Derived: 9-month figure less the 6-month figure.Report this figure(1,591)Free cash flow, Q4 FY2025, three months to 2025-04-30. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(1,472)Free cash flow, Q3 FY2026, three months to 2026-01-31. operating cash flow − capital expenditureOperating cash flow: −$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-16, accession 0001437749-26-008399. Derived: 9-month figure less the 6-month figure.Capital expenditure: −$9.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-03-16, accession 0001437749-26-008399. Derived: 9-month figure less the 6-month figure.Report this figure(1,677)Free cash flow, Q4 FY2026, three months to 2026-04-30. operating cash flow − capital expenditureOperating cash flow: −$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-23, accession 0001437749-26-024337. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$4.3kGross margin 59.1%
Diluted EPS−$9.34, FY2025
Free cash flow−$7.4m, FY2026
HeartSciences Inc., key figures for the last five fiscal years
Line itemUnitFY2022-04-30FY20232023-04-30FY20242024-04-30FY20252025-04-30FY20262026-04-30Shape over the periods
Revenue$k14.4Revenue, period not labelled, twelve months to 2022-04-30$14.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure5.2Revenue, FY2023, twelve months to 2023-04-30$5.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure18.6Revenue, FY2024, twelve months to 2024-04-30$18.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure4.4Revenue, FY2025, twelve months to 2025-04-30$4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure4.3Revenue, FY2026, twelve months to 2026-04-30$4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure
Gross margin%45.1%Gross margin, period not labelled, twelve months to 2022-04-30. gross profit / revenueGross profit: $6.5k. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-07-19, accession 0000950170-23-033424.Revenue: $14.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure45.7%Gross margin, FY2023, twelve months to 2023-04-30. gross profit / revenueGross profit: $2.4k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-07-29, accession 0000950170-24-087271.Revenue: $5.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure67.3%Gross margin, FY2024, twelve months to 2024-04-30. gross profit / revenueGross profit: $12.5k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-07-24, accession 0000950170-25-098326.Revenue: $18.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure56.8%Gross margin, FY2025, twelve months to 2025-04-30. gross profit / revenueGross profit: $2.5k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure59.1%Gross margin, FY2026, twelve months to 2026-04-30. gross profit / revenueGross profit: $2.6k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure
Operating margin%(32765.6%)Operating margin, period not labelled, twelve months to 2022-04-30. operating income / revenueOperating income: −$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-07-19, accession 0000950170-23-033424.Revenue: $14.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure(118698.3%)Operating margin, FY2023, twelve months to 2023-04-30. operating income / revenueOperating income: −$6.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-07-29, accession 0000950170-24-087271.Revenue: $5.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure(33902.0%)Operating margin, FY2024, twelve months to 2024-04-30. operating income / revenueOperating income: −$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-07-24, accession 0000950170-25-098326.Revenue: $18.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure(192013.1%)Operating margin, FY2025, twelve months to 2025-04-30. operating income / revenueOperating income: −$8.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure(194787.4%)Operating margin, FY2026, twelve months to 2026-04-30. operating income / revenueOperating income: −$8.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure
Net margin%(33592.6%)Net margin, period not labelled, twelve months to 2022-04-30. net income / revenueNet income: −$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-07-19, accession 0000950170-23-033424.Revenue: $14.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure(123384.3%)Net margin, FY2023, twelve months to 2023-04-30. net income / revenueNet income: −$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-07-29, accession 0000950170-24-087271.Revenue: $5.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure(35511.9%)Net margin, FY2024, twelve months to 2024-04-30. net income / revenueNet income: −$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-07-24, accession 0000950170-25-098326.Revenue: $18.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure(201499.5%)Net margin, FY2025, twelve months to 2025-04-30. net income / revenueNet income: −$8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure(211666.5%)Net margin, FY2026, twelve months to 2026-04-30. net income / revenueNet income: −$9.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-23, accession 0001437749-26-024337.Revenue: $4.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure
Diluted EPS$ per share(1.45)Diluted EPS, period not labelled, twelve months to 2022-04-30−$1.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure(80.00)Diluted EPS, FY2023, twelve months to 2023-04-30−$80.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure(18.74)Diluted EPS, FY2024, twelve months to 2024-04-30−$18.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure(9.34)Diluted EPS, FY2025, twelve months to 2025-04-30−$9.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figurenot reported (Diluted EPS not reported)
Free cash flow$k(3,646)Free cash flow, period not labelled, twelve months to 2022-04-30. operating cash flow − capital expenditureOperating cash flow: −$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-07-19, accession 0000950170-23-033424.Capital expenditure: $1.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-07-19, accession 0000950170-23-033424.Report this figure(5,792)Free cash flow, FY2023, twelve months to 2023-04-30. operating cash flow − capital expenditureOperating cash flow: −$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-07-29, accession 0000950170-24-087271.Capital expenditure: $18.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-07-29, accession 0000950170-24-087271.Report this figure(6,135)Free cash flow, FY2024, twelve months to 2024-04-30. operating cash flow − capital expenditureOperating cash flow: −$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-07-24, accession 0000950170-25-098326.Capital expenditure: $64.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-07-24, accession 0000950170-25-098326.Report this figure(7,416)Free cash flow, FY2025, twelve months to 2025-04-30. operating cash flow − capital expenditureOperating cash flow: −$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-23, accession 0001437749-26-024337.Capital expenditure: $3.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure(7,430)Free cash flow, FY2026, twelve months to 2026-04-30. operating cash flow − capital expenditureOperating cash flow: −$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-23, accession 0001437749-26-024337.Capital expenditure: $3.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-23, accession 0001437749-26-024337.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding HeartSciences Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
TFB Advisors LLC2026-06-30$74.6k29,740Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$57.9k23,049Reduced−5,889
Astoria Strategic Wealth, Inc.2026-06-30$47.5k18,927Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$45.1k17,968Unchanged
VANGUARD FIDUCIARY TRUST CO2026-06-30$43.3k17,239Unchanged
Tradition Wealth Management, LLC2026-06-30$42.2k16,819Unchanged
CITADEL ADVISORS LLC2026-06-30$36.4k14,488New+14,488
CITIGROUP INC2026-06-30$14.7k5,859New+5,859
UBS Group AG2026-06-30$14.6k5,812Reduced−664
Clear Street Group Inc.2026-06-30$13.6k270,770Unchanged

Recent filings

All 341 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

HeartSciences Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2321:30 ETSCHEDULE 13D/AOwnership report, active investor, amended0001213900-26-112224
2026-10-0616:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-107238
2026-10-0217:15 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-26-106500
2026-09-1708:01 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-100752
2026-09-1517:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-26-100185
2026-09-1416:14 ET10-QQuarterly reportPeriod 2026-07-310001437749-26-030319
2026-08-2007:43 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-091893
2026-08-1917:11 ET8-K/A9.01 Financial statements and exhibits0001213900-26-091764
2026-08-1916:45 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-091720
2026-08-1820:13 ETSCHEDULE 13DOwnership report, active investor0001213900-26-091367

Latest annual report

Form 10-K for the fiscal year ended Apr 30, 2026Filed Jul 23, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1468492
Tickers
HSCS, HSCSW
Exchange
Nasdaq
SIC code
6199 Finance Services
Sector
Financials
Fiscal year ends
Apr 30
Incorporated in
TX
Filer category
<br>Emerging growth company
Former names
Heart Test Laboratories, Inc. (to 2024-10-18)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:13 ET. Listed shows no prices and gives no investment advice.